Evidence map›Paper›PMID 25392218›Full record

ArticleJournal of virology2015

Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.

Tatyana Yun, Arnold Park, Terence E Hill, Olivier Pernet, Shannon M Beaty, Terry L Juelich, Jennifer K Smith, Lihong Zhang, Yao E Wang, Frederic Vigant and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Strengthening preparedness and response to emerging henipavirus diversity.Frontiers in cellular and infection microbiology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Nipah virus: pathogenesis, genome, diagnosis, and treatment.Applied microbiology and biotechnology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Tatyana YunDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Arnold ParkDepartment of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Terence E HillDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Olivier PernetDepartment of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA.
Shannon M BeatyDepartment of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Terry L JuelichDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Jennifer K SmithDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Lihong ZhangDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Yao E WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA.
Frederic VigantDepartment of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Junling GaoDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Ping WuDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Benhur LeeDepartment of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, Los Angeles, California, USA Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Benhur.Lee@mssm.edu anfreibe@utmb.edu.
Alexander N FreibergDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA Benhur.Lee@mssm.edu anfreibe@utmb.edu.
The University of Texas Medical Branch at Galveston · USUniversity of California, Los Angeles · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8M
WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6M
Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5M
MULTIDISCIPLINARY TRAINING IN MICROBIAL PATHOGENESIST32AI007323 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peter John Bradley · 1988 to 2026
$8.6M
Training in Emerging Infectious Diseases and BiodefenseT32AI007536 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WHITE, ARTHUR CLINTON · 1998 to 2013
$4.1M
Nipah Virus Pathobiology and Effects on Innate ImmunityR01AI060694 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BAUM, LINDA G · 2005 to 2009
$1.8M
Envelope-receptor interactions in Nipah and Hendra virus pathobiologyR01AI069317 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEE, BENHUR · 2007 to 2011
$1.7M
A reverse genetic system for the study of Nipah VirusR21AI059051 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEE, BENHUR · 2004 to 2005
$609k
NIAID NIH HHS R01 AI060694NIAID NIH HHS R01 AI069317NIAID NIH HHS R21 AI059051NIAID NIH HHS T32 AI007323NIAID NIH HHS T32 AI007536NIAID NIH HHS T32 AI007647NIAID NIH HHS T32 AI007647-15NIAID NIH HHS T32 AI07323NIAID NIH HHS U54 AI057156NIAID NIH HHS U54 AI065359NIAID NIH HHS UC7 AI094660NIGMS NIH HHS GM007185NIGMS NIH HHS T32 GM007185
6 · The paper itself

Abstract

unlabelledNipah virus (NiV) and Hendra virus (HeV) are closely related henipaviruses of the Paramyxovirinae. Spillover from their fruit bat reservoirs can cause severe disease in humans and livestock. Despite their high sequence similarity, NiV and HeV exhibit apparent differences in receptor and tissue tropism, envelope-mediated fusogenicity, replicative fitness, and other pathophysiologic manifestations. To investigate the molecular basis for these differences, we first established a highly efficient reverse genetics system that increased rescue titers by ≥3 log units, which offset the difficulty of generating multiple recombinants under constraining biosafety level 4 (BSL-4) conditions. We then replaced, singly and in combination, the matrix (M), fusion (F), and attachment glycoprotein (G) genes in mCherry-expressing recombinant NiV (rNiV) with their HeV counterparts. These chimeric but isogenic rNiVs replicated well in primary human endothelial and neuronal cells, indicating efficient heterotypic complementation. The determinants of budding efficiency, fusogenicity, and replicative fitness were dissociable: HeV-M budded more efficiently than NiV-M, accounting for the higher replicative titers of HeV-M-bearing chimeras at early times, while the enhanced fusogenicity of NiV-G-bearing chimeras did not correlate with increased replicative fitness. Furthermore, to facilitate spatiotemporal studies on henipavirus pathogenesis, we generated a firefly luciferase-expressing NiV and monitored virus replication and spread in infected interferon alpha/beta receptor knockout mice via bioluminescence imaging. While intraperitoneal inoculation resulted in neuroinvasion following systemic spread and replication in the respiratory tract, intranasal inoculation resulted in confined spread to regions corresponding to olfactory bulbs and salivary glands before subsequent neuroinvasion. This optimized henipavirus reverse genetics system will facilitate future investigations into the growing numbers of novel henipavirus-like viruses. IMPORTANCE: Nipah virus (NiV) and Hendra virus (HeV) are recently emergent zoonotic and highly lethal pathogens with pandemic potential. Although differences have been observed between NiV and HeV replication and pathogenesis, the molecular basis for these differences has not been examined. In this study, we established a highly efficient system to reverse engineer changes into replication-competent NiV and HeV, which facilitated the generation of reporter-expressing viruses and recombinant NiV-HeV chimeras with substitutions in the genes responsible for viral exit (the M gene, critical for assembly and budding) and viral entry (the G [attachment] and F [fusion] genes). These chimeras revealed differences in the budding and fusogenic properties of the M and G proteins, respectively, which help explain previously observed differences between NiV and HeV. Finally, to facilitate future in vivo studies, we monitored the replication and spread of a bioluminescent reporter-expressing NiV in susceptible mice; this is the first time such in vivo imaging has been performed under BSL-4 conditions.

Indexed as

Disease Models, AnimalVirus InternalizationVirus ReleaseAnimalsGenetic Complementation TestHendra VirusHenipavirus InfectionsHumansMice, KnockoutNipah VirusRecombination, GeneticReverse GeneticsViral Tropism

Identifiers

PMID25392218
PMCPMC4300668
OpenAlexW2100137876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.